European Journal of Cancer
Volume 42, Issue 15 , Pages 2425-2432 , October 2006

A genomic explanation connecting “Mediterranean diet”, olive oil and cancer: Oleic acid, the main monounsaturated Fatty acid of olive oil, induces formation of inhibitory “PEA3 transcription factor-PEA3 DNA binding site” complexes at the Her-2/neu (erbB-2) oncogene promoter in breast, ovarian and stomach cancer cells

  • Javier A. Menendez

      Affiliations

    • Department of Medicine, Evanston Northwestern Healthcare Research Institute, 1001 University Place, Evanston, IL 60201, USA
    • Department of Medicine, Northwestern University Feinberg, School of Medicine, Chicago, IL, USA
    • Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA
    • ,
  • Adriana Papadimitropoulou

      Affiliations

    • Department of Medicine, Evanston Northwestern Healthcare Research Institute, 1001 University Place, Evanston, IL 60201, USA
    • Department of Medicine, Northwestern University Feinberg, School of Medicine, Chicago, IL, USA
    • ,
  • Luciano Vellon

      Affiliations

    • Department of Medicine, Evanston Northwestern Healthcare Research Institute, 1001 University Place, Evanston, IL 60201, USA
    • Department of Medicine, Northwestern University Feinberg, School of Medicine, Chicago, IL, USA
    • ,
  • Ruth Lupu

      Affiliations

    • Department of Medicine, Evanston Northwestern Healthcare Research Institute, 1001 University Place, Evanston, IL 60201, USA
    • Department of Medicine, Northwestern University Feinberg, School of Medicine, Chicago, IL, USA
    • Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA
    • Corresponding Author InformationCorresponding author: Tel.: +1 224 364 7671/7672; fax: +1 847 570 8022.

Received 16 August 2005 ,Accepted 3 October 2005.

References 

  1. Martin-Moreno JM, Willett P, Gorgojo L, et al. Dietary fat, olive oil intake and breast cancer risk. Int J Cancer. 1994;58:774–780
  2. Landa MC, Frago N, Tres A. Diet and risk of breast cancer in Spain. Eur J Cancer Prev. 1994;3:313–320
  3. Trichopoulou A, Katsouyanni K, Stuver S, et al. Consumption of olive oil and specific food groups in relation to breast cancer risk in Greece. J Natl Cancer Inst. 1995;87:110–116
  4. La Vecchia C, Negri E, Franceschi S, et al. Olive oil, other dietary fats, and the risk of breast cancer. Cancer Causes Control. 1995;6:545–550
  5. Simonsen NR, Fernandez-Crehuet NJ, Martin-Moreno JM, et al. Tissue stores of individual monounsaturated fatty acids and breast cancer: the EURAMIC study. European Community Multicenter Study on antioxidants, myocardial infarction, and breast cancer. Am J Clin Nutr. 1998;68:134–141
  6. Stoneham M, Goldacre M, Seagroatt V, et al. Olive oil, diet and colorectal cancer: an ecological study and a hypothesis. J Epidemiol Community Health. 2000;54:756–760
  7. Braga C, La Vecchia C, Franceschi S, et al. Olive oil, other seasoning fats, and the risk of colorectal carcinoma. Cancer. 1998;82:448–453
  8. Tzonou A, Hsieh C, Polychronopoulou A, et al. Diet and ovarian cancer: a case-control study in Greece. Int J Cancer. 1993;55:411–414
  9. Tzonou A, Lipworth L, Kalandidi A, et al. Dietary factors and the risk of endometrial cancer: a case-control study in Greece. Br J Cancer. 1996;73:1284–1290
  10. Zamora-Ardoy MA, Banez Sanchez F, Banez Sanchez C, et al. Olive oil: influence and benefits on some pathologies. An Med Interna. 2004;21:138–142
  11. Martin-Moreno JM. The role of olive oil in lowering cancer risk: is the real gold or simply pinchbeck?. J Epidemiol Community Health. 2000;54:726–727
  12. Menendez JA, Ropero S, Lupu R, et al. Dietary fatty acids regulate the activation status of Her-2/neu (c-erbB-2) oncogene in breast cancer cells. Ann Oncol. 2004;15:1719–1721
  13. Menendez JA, Vellon L, Colomer R, et al. Oleic acid, the main monounsaturated fatty acid of olive oil, suppresses Her-2/neu (erbB-2) expression and synergistically enhances the growth inhibitory effects of trastuzumab (Herceptin) in breast cancer cells with Her-2/neu gene amplification. Ann Oncol. 2005;16:359–371
  14. Yamamoto T, Ikawa S, Akiyama T, et al. Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor. Nature. 1986;319:230–234
  15. Bargmann CI, Hung M-C, Weinberg RA. The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature. 1986;319:226–230
  16. Daly RJ. Take your partners, please–signal diversification by the erbB family of receptor tyrosine kinases. Growth Factors. 1999;16:255–263
  17. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001;2:127–137
  18. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177–182
  19. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244:707–712
  20. Ross JS, Fletcher JA. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells. 1998;16:413–428
  21. Di Fiore PP, Pierce JH, Kraus MH, et al. erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science. 1987;237:178–182
  22. Hudziak RM, Schlessinger J, Ullrich A. Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumourigenesis of NIH 3T3 cells. Proc Natl Acad Sci USA. 1987;84:7159–7163
  23. Tan M, Yao J, Yu D. Overexpression of the c-erbB-2 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transformation abilities. Cancer Res. 1997;57:1199–1205
  24. Eccles SA. The role of c-erbB-2/HER2/neu in breast cancer progression and metastasis. J Mammary Gland Biol Neoplasia. 2001;6:393–406
  25. Yu D, Hung M-C. Role of erbB2 in breast cancer chemosensitivity. Bioessays. 2000;22:673–680
  26. Dowsett M. Overexpression of HER-2 as a resistance mechanism to hormonal therapy for breast cancer. Endocrinol Relat Cancer. 2001;8:191–195
  27. Marchetti P. Natural medicine: a ‘new frontier’ in oncology?. Ann Oncol. 2005;16:339–340
  28. Nelson R. Oleic acid suppresses overexpression of ERBB2 oncogene. Lancet Oncol. 2005;6:69
  29. Kraus MH, Popescu NC, Amsbaugh SC, et al. Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumour cell lines by different molecular mechanisms. EMBO J. 1987;6:605–610
  30. Bates NP, Hurst HC. Transcriptional regulation of type I receptor tyrosine kinases in the mammary gland. J Mammary Gland Biol Neoplasia. 1997;2:153–163
  31. Hurst HC. Update on HER-2 as a target for cancer therapy. The ERBB2 promoter and its exploitation for cancer treatment. Breast Cancer Res. 2001;3:395–398
  32. Bosher JM, Williams T, Hurst HC. The developmentally regulated transcription factor AP-2 is involved in c-erbB-2 overexpression in human mammary carcinoma. Proc Natl Acad Sci USA. 1995;92:744–747
  33. Bosher JM, Totty NF, Hsuan JJ, et al. A family of AP-2 proteins regulates c-erbB-2 expression in mammary carcinoma. Oncogene. 1996;13:1701–1707
  34. Vernimmen D, Gueders M, Pisvin S, et al. Different mechanisms are implicated in ERBB2 gene overexpression in breast and in other cancers. Br J Cancer. 2003;89:899–906
  35. Xing X, Wang SC, Xia W, et al. The ets protein PEA3 suppresses HER-2/neu overexpression and inhibits tumourigenesis. Nat Med. 2000;6:189–195
  36. Wang SC, Hung M-C. Transcriptional targeting of the HER-2/neu oncogene. Drugs Today (Barc). 2000;36:835–843
  37. Benz CC, Scott GK, Sarup JC, et al. Estrogen-dependent, tamoxifen-resistant tumourigenic growth of MCF-7 cells transfected with Her-2/neu. Breast Cancer Res Treat. 1993;24:85–95
  38. Carter P, Presta L, Gorman CM, et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA. 1992;89:4285–4289
  39. Baselga J, Tripathy D, Mendelsohn J, et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol. 1996;14:737–744
  40. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999;17:2639–2648
  41. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002;20:719–726
  42. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783–792
  43. Allen LF, Eiseman IA, Fry DW, et al. CI-1033, an irreversible pan-erbB receptor inhibitor and its potential for the treatment of breast cancer. Semin Oncol. 2003;30(5 Suppl. 16):65–78
  44. Burris HA. Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib. Oncologist. 2004;9(Suppl. 3):10–15
  45. Wang SC, Zhang L, Hortobagyi GN, et al. Targeting HER2: recent developments and future directions for breast cancer patients. Semin Oncol. 2001;28(6 Suppl 18):21–29
  46. Lu Y, Zi X, Zhao Y, et al. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst. 2001;93:1852–1857
  47. Nagata Y, Lan KH, Zhou X, et al. PTEN activation contributes to tumour inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell. 2004;6:117–127
  48. Scott GK, Chang CH, Erny KM, et al. Ets regulation of the erbB2 promoter. Oncogene. 2000;19(2):153–163

PII: S0959-8049(05)00935-4

doi: 10.1016/j.ejca.2005.10.016

European Journal of Cancer
Volume 42, Issue 15 , Pages 2425-2432 , October 2006

Article Tools

* Image Usage & Resolution